|
Oct 1
|
Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism
|
|
Sep 24
|
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
|
|
Jun 18
|
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
|
|
Jun 18
|
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even
|
|
Jan 15
|
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
|
|
Jan 12
|
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
|
|
Dec 7
|
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
|